These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25966992)

  • 21. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
    Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
    Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
    World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero.
    de Lima A; Kanis SL; Escher JC; van der Woude CJ
    J Crohns Colitis; 2018 Jul; 12(8):948-953. PubMed ID: 29726943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate-severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight.
    Kammerlander H; Nielsen J; Knudsen T; Kjeldsen J; Friedman S; Nørgård BM
    Inflamm Bowel Dis; 2017 Nov; 23(11):1916-1923. PubMed ID: 28858070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system.
    Wieringa JW; Driessen GJ; Van Der Woude CJ
    Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):811-818. PubMed ID: 29972674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy.
    Zelinkova Z; de Haar C; de Ridder L; Pierik MJ; Kuipers EJ; Peppelenbosch MP; van der Woude CJ
    Aliment Pharmacol Ther; 2011 May; 33(9):1053-8. PubMed ID: 21366638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.
    Shihab Z; Yeomans ND; De Cruz P
    J Crohns Colitis; 2016 Aug; 10(8):979-88. PubMed ID: 26755733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies.
    de Lima-Karagiannis A; Zelinkova-Detkova Z; van der Woude CJ
    Am J Gastroenterol; 2016 Sep; 111(9):1305-12. PubMed ID: 27349339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
    Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
    Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
    Colman RJ; Rubin DT
    J Crohns Colitis; 2015 Apr; 9(4):312-7. PubMed ID: 25616487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.
    Marchioni RM; Lichtenstein GR
    World J Gastroenterol; 2013 May; 19(17):2591-602. PubMed ID: 23674866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.
    Gisbert JP; Chaparro M
    Am J Gastroenterol; 2013 Sep; 108(9):1426-38. PubMed ID: 23752881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are anti-TNF drugs safe for pregnant women with inflammatory bowel disease?
    Brennan GT; Duong A; Nguyen ET; Nguyen DL
    Cleve Clin J Med; 2018 Dec; 85(12):923-924. PubMed ID: 30526752
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease.
    Gholam-Mostafaei FS; Yadegar A; Aghdaei HA; Azimirad M; Daryani NE; Zali MR
    Curr Res Transl Med; 2020 Aug; 68(3):125-130. PubMed ID: 32414632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
    J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
    Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
    Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease.
    Kammerlander H; Nielsen J; Kjeldsen J; Knudsen T; Friedman S; Nørgård B
    Inflamm Bowel Dis; 2017 Jun; 23(6):1011-1018. PubMed ID: 28346274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
    Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C
    United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.